DNA Analysis in Glycogen storage disease

Similar documents
Non-Lysosomal Glycogen Storage Disorders Biochemical Diagnosis

Supplementary Table 2. Identified causative mutations and/or mutation candidates.

Glycogen function. Cellular glucose store. Local emergency store Local short term use

number Done by Corrected by Doctor Nayef Karadsheh

Diseases Associated with Glycogen Synthesis

The concentration of glucose residues stored as glycogen in liver is ~0.4M, Whereas, glycogen concentration is only 10 nm.

Structure. Lysosomes are membrane-enclosed organelles. Hydrolytic enzymes. Variable in size & shape need

7 Medical Genetics. Hemoglobinopathies. Hemoglobinopathies. Protein and Gene Structure. and Biochemical Genetics

Biochemistry Team 437. Glycogen metabolism. Color index: Doctors slides Notes and explanations Extra information Highlights. Musculoskeletal block

Whole Exome Sequenced Characteristics

ESPEN Congress Madrid 2018

Metabolism of pentoses, glycogen, fructose and galactose. Jana Novotna

Lecture 3: Phosphorylase (parts of Chapter 15 + Buchbinder et al. 2001) Discussion of paper and talk assignments.

There are four different forms of Tarui disease, which are classed by their signs and symptoms and age of presentation.

Not Your Typical Case of Ketotic Hypoglycemia

Glycogen Storage Disease Type III, VI and IX - basics -

Chapter 15 Homework Assignment

Pompe. Lysosomal Disorders. Introduction

Muscle Metabolism. Dr. Nabil Bashir

Whole exome sequencing as a first line test: Is there even a role for metabolic biochemists in the future?

Glycogen Metabolism. BCH 340 lecture 9

Familial exudative vitreoretinopathy (FEVR) is an inheritable

Belgian study into von Willebrand Disease (B-Will): First results

Spectrum and Classification of ATP7B Variants in a Large Cohort of Chinese Patients with Wilson s Disease Guides Genetic Diagnosis

Link download full of Test Bank for Fundamentals of Biochemistry 4th Edition by Voet

July 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label)

2. What is molecular oxygen directly converted into? a. Carbon Dioxide b. Water c. Glucose d. None of the Above

Carbohydrate. Metabolism

Nature Genetics: doi: /ng Supplementary Figure 1. TCGA data set on HNSCCs reanalyzed in this study.

Supplementary Table 1. PIK3CA mutation in colorectal cancer

Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency

Comparison of catabolic and anabolic pathways

Metabolic Myopathies. Review Article. Alejandro Tobon, MD ABSTRACT

Biology 638 Biochemistry II Exam-2

By: Dr Hadi Mozafari 1

CHY2026: General Biochemistry UNIT 7& 8: CARBOHYDRATE METABOLISM

Pompe Disease. Family Education Booklet. Division of Pediatric Genetics Metabolism and Genomic Medicine

Lecture 34. Carbohydrate Metabolism 2. Glycogen. Key Concepts. Biochemistry and regulation of glycogen degradation

Belgian-Czech cooperation in the Brno-VWD study

Supplementary Online Content

Exomes and Beyond Addressing the Genome with OneSeq. Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA

Glycogen metabolism and glycogen storage disorders

Pompe s Disease and the Effects of Alpha- Glucosidase Deficiency

Robert Barski. Biochemical Genetics St James s University Hospital, Leeds. MetBioNet IEM Introductory Training

Best Practice & Research Clinical Gastroenterology

BIOCHEMICAL AND MOLECULAR HETEROGENEITY IN CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY

Pathway overview. Glucose + 2NAD + + 2ADP +2Pi 2NADH + 2pyruvate + 2ATP + 2H 2 O + 4H +

Clinical presentation. Duration (Month)

Characterisation of the Ovine Model of McArdle s Disease: Development of Therapeutic Strategies. Kendall Rae Walker BSc (Hons.)

I tried to put as many questions as possible, but unfortunately only answers were found without the questions.

I tried to put as many questions as possible, but unfortunately only answers were found without the questions.

Glycogen Storage Diseases (A group of genetic diseases)

Supplementary appendix

Case Report A Novel Nonsense Mutation of the AGL Gene in a Romanian Patient with Glycogen Storage Disease Type IIIa

National Metabolic Biochemistry Network Guidelines for the investigation of hypoglycaemia in infants and children

40%7 of normal. In addition, the liver glycogen isolated

Laboratory, Division of Medical Sciences, National Cancer Centre, Singapore

Metabolic Muscle Diseases

Carbohydrate Metabolism 2 Supplemental Reading

Diagnostic difficulties in prevention and control program for thalassemia in Thailand: atypical thalassemia carriers

NCG Diagnostic and Management Service for McArdle Disease and Related Disorders Lead clinician: Dr Ros Quinlivan

DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE

CARBOHYDRATE METABOLISM 1

Biochemistry. Glycogenolysis. Metabolism of Carbohydrates. Dr.S.K.Khare,Professor IIT Delhi. Principal Investigator

Supplementary Figure 1

Glucose is the only source of energy in red blood cells. Under starvation conditions ketone bodies become a source of energy for the brain

UW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA

Chapter 18: Carbohydrate Metabolism

Chapter 22. Before the class. 10 Steps of glycolysis. Outline. Can you tell the ten steps of glycolysis? Do you know how glucoses are

Integration of Metabolism

PRINT your Name Student (FAMILY, first name) Midterm 7:00 P.M.

Investigation and management of the hepatic glycogen storage diseases

Glycogen Storage Disease Type I

Carbohydrate Metabolism - 4. Lecturer KOVAL Alexander N. PhD, senior lecturer

Chemistry 5.07SC Biological Chemistry I Fall Semester, 2013

Newborn Screening and Studies of Lysosomal Storage Diseases in CFOH

HEREDITARY METABOLIC DISEASES

Human inherited diseases

Presentation and investigation of mitochondrial disease in children

Glycolysis. Degradation of Glucose to yield pyruvate

Genética e Hígado: Cómo contribuye la genética en el algoritmo diagnóstico de la enfermedad hepática pediátrica? Nicholas Ah Mew, MD

e-learning Fatty Acid Oxidation Defects Camilla Reed and Dr Simon Olpin Sheffield Children s Hospital

Supplementary Information

Dr. Mohnen s notes on GLUCONEOGENESIS

Mutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark

Carbohydrate metabolism 3. Atip Likidlilid

Glycogen Storage Disease

BIOL212- Biochemistry of Disease. Metabolic Disorders: Diabetes

MetBioNet Best Practice Guidelines. Investigation of an inherited metabolic cause of cardiomyopathy

Divine Intervention Episode 51 Comprehensive Step 1 Biochemistry Review (Session 2) Some PGY1

Glycolysis is the sequence of reactions that metabolize one molecule of glucose into two molecules of pyruvate with the production of two molecules

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Summary of Results CARRIER STATUS DNA INSIGHT. Result: Carrier, Heterozygote. Protected Health Information. Propionic Acidemia

Hepatic glycogen storage disorders: what have we learned in recent years?

GLYCOLYSIS Generation of ATP from Metabolic Fuels

CELLULAR GLYCOGEN Why Glycogen as an Energy Storage Molecule? Glycogenolysis NOT phosphorolysis

Clinical Spectrum and Genetic Mechanism of GLUT1-DS. Yasushi ITO (Tokyo Women s Medical University, Japan)

0.40. Biochemistry of Carbohydrates

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still

Infantile-onset glycogen storage disease type II

Transcription:

DNA Analysis in Glycogen storage disease Nick Beauchamp PhD Sheffield, Sheffield Children s NHS Foundation Trust 14th October 2010

Glycogen Synthase Type 0 Glycogen Synthesis and Breakdown Type IV UDPGlucose Uridine Diphosphoglucose Pyrophosphorylase Glucose Branching Enzyme Glucokinase Alpha-1,6 Phosphoglucose Isomerase Glycogen Alpha-1,4 Glucose 1-P Glucose 6-P Type IX Sheffield Phosphorylase Kinase Phosphorylase Limit dextrin Type V and VI Debranching Enzyme G-6-Phosphatase Glucose Type III Type I

Glycogen Synthesis and Breakdown Glycogen Synthase Branching Enzyme Glycogen Sheffield Phosphorylase Kinase Phosphorylase UDPGlucose Alpha-1,6 Limit dextrin Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose Type Ia Type Ib G6PC gene SLC37A4 gene

GSD Type I First described by von Gierke in 1929 Approx 1 in 58,000 newborns affected Autosomal recessive Classification: Ia: Deficiency of glucose-6-phosphatase enzyme Ib/Inon-a: Deficiency of glucose-6-phosphate transporter Approx 10% of Type 1 cases are Ib

Mutations identified Type Ia G6PC gene 5 exons, 13 kb on Chr 17q21 >80 mutations reported Common changes: p.arg83cys -32% p.gln347x -22%

G6PC gene mutations From Foster and Nordlie 2002. Exp Biol Med 227: 601-608.

Mutations identified Type Ib SLC37A4 gene 9 exons, 6 kb on Chr 11q23.3 >65 mutations reported Common changes: p.leu348fs -28% p.gly339cys -19%

SLC37A4 gene mutations From Foster and Nordlie 2002. Exp Biol Med 227: 601-608.

Genetic Analysis in GSD type I Avoids liver biopsy Confirms diagnosis - type Ia versus Ib No clear genotype/phenotype correlation

Glycogen Synthesis and Breakdown Glycogen Synthase Branching Enzyme UDPGlucose Alpha-1,6 Glycogen Sheffield Phosphorylase Kinase Phosphorylase Limit dextrin Type V and VI PYGM and PYGL genes Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose

GSD Type V Also known as McArdle Disease Deficiency of muscle glycogen phosphorylase cleaves α-1,4-glucosidic bonds Autosomal recessive PYGM gene 20 exons, 40kb on Chr 11q12-q13.2 2.5% of GSDs

Mutations of the PYGM gene Common mutations: p.arg50x - 32% -81% of alleles p.gly205ser -0% -10% of alleles Other mutations >85 rare mutations Non-sense mediated mrna decay

Mutations of the PYGM gene From Rubio et al 2007. Human Mutation 28: 203-204

GSD Type VI Also known as Hers Disease Deficiency of liver glycogen phosphorylase Autosomal recessive PYGL gene Rare 20 exons, 40kb on Chr 14q21-q22

GSD Type VI - Reported Patients 11 patients published with 17 mutations Majority are missense mutations Clustered in exons 16 and 17 [c.1964_1969inv6;c.1969+1_+4delgtac] c.1768+1g>a c.1620+1g>a p.m1? c.529-1g>c p.r399x PYGL p.q13p p.g233d p.r491c p.v456m p.n632i p.n339s p.n377k p.d634h p.e673k p.s675t p.k681t p.s675l

GSD Type VI - Screened Patients All published patients and 16 patients from clinical service c.345g>a p.m1? [c.1964_1969inv6;c.1969+1_+4delgtac] c.1768+1g>a p.q577x c.1620+1g>a c.1000-1g>a c.1518g>a c.529-1g>c p.r399x PYGL p.q13p p.g233d p.r491c p.s836f p.d307g p.v456m p.n632i p.y821h p.n339s p.d634h p.g686a p.n377k p.e673k p.s675t p.k681t p.s675l

GlycogenPhosphorylase Pyridoxal Phosphate Glycogen + P i Active Site Glycogen + Glucose-1-P

Glycogen Synthesis and Breakdown Glycogen Synthase Branching Enzyme Glycogen PHKA2 gene PHKG2 gene PHKB gene Sheffield Phosphorylase Kinase Phosphorylase Type IX UDPGlucose Alpha-1,6 Limit dextrin Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose

Phosphorylase kinase Four copies of each of α, β, γ, δ subunits Sheffield From: Vénien-Bryan et al 2009 Structure 17: 117 127.

X-linked GSD Type IX Deficiency of liver α subunit (PHKA2 gene) Clinical symptoms Hepatomegaly Liver dysfunction Hypoglycaemia Growth retardation Elevated blood cholesterol, triglycerides Mild muscle hypotonia in some cases

X-linked GSD Type IX X-Linked Glycogenosis type 1 (XLG1) Reduced PHK activity in RBC and liver X-Linked Glycogenosis type 2 (XLG2) Reduced PHK activity in liver only

XLG1 α Chain p.f141del p.y116d p.c91y p.r45q p.s201y p.g292r p.r295h p.r916w p.p869r p.q818_y825del8 p.p399s p.i566n p.m1113i p.r1070del p.e1125k p.m1170dup p.p1205l p.g1207w p.g1210e p.w43r p.r45w p.c326r p.p498l p.e893k p.e1117k p.y116_t120dup p.d299g p.t1114i p.h132y p.r295c p.1111_1112instr p.h132p p.r295h p.r186c p.r295l p.r186h p.t251del Multiphosphorylation domain p.k189e p.g193v p.k189_t190del XLG2

Case 1 Symptoms present at 1 year, diagnosed type VI at 7 years Hepatomegaly Normal fasting Raised transaminases Growth retardation WBC Total GP: 1.4 (NR: 1.0-3.2 µmol Pi/mg alb/h) WBC Activated GP: 0.3 (NR: 0.5-2.2 µmol Pi/mg alb/h) RBC PHK: 21.8 (NR: 8.6-45 µmol Pi/min/g Hb) No mutation identified in PYGL gene Not GSD type VI Analysis of PHKA2: p.arg182cys X-linked GSD Type IX

Autosomal GSD Type IX Autosomal recessive Rarer then X-linked form Deficiency of either β or liver γ subunit Mutations in PHKB gene 33 exons, 238kb on Chr 16q12-q13 or PHKG2 gene 10 exons, 9kb on Chr 7p11.2

Autosomal GSD Type IX Deficiency of β subunit Very mild symptoms Hepatomegaly Hypoglycaemia in rare cases with prolonged fasting Deficiency of liver γ subunit Severe hepatomegaly Liver dysfunction Recurrent hypoglycaemia Growth retardation Fibrosis of the liver leading to cirrhosis and adenomata

ß Chain p.a118p p.m185i p.q657k Exon Mutaton Predicted Effect 5 c.306-2a>g Deletion of exon 5 8 7574 bp deletion Deletion of exon 8 14 c.1257t>a p.y419x 14 c.1275dupa p.n422kfsx2 14 c.1285c>t p.r429x 20 c.1827g>a p.w609x 21 c.1969c>t p.q657x 27 c.2337-2a>c Deletion of exon 27 31 c.2926g>t d p.e976x 31 c.2896-1g>t c.2896_2911del16 γ Chain p.e157k p.h145y p.v106e p.l144p p.g189e p.d215n p.l226r Exon Mutaton Predicted Effect 3 c.131c>t p.r44x 3 c.144delc p.h48qfsx5 3 c.265dupc p.h89pfsx14 4 c.277delc p.l93sfsx18 4 c.326+1g>a Deletion of exon 4 9 c.900g>a p.w300x

Genetic Analysis Confirms the diagnosis Distinguishes GSD type VI from GSD type IX -XLG2 Identifies the subunit deficient and thus prognosis Identifies the inheritance Allowing family studies

Glycogen Synthesis and Breakdown Glycogen Synthase Branching Enzyme Glycogen Sheffield Phosphorylase Kinase Phosphorylase UDPGlucose Alpha-1,6 Limit dextrin Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme Type III AGL gene G-6-Phosphatase Glucose

GSD Type III Also known as Cori or Forbes Disease Deficiency of glycogen debrancher enzyme Autosomal recessive Four subtypes: Type IIIa (~85% of patients) Enzyme deficient in both liver and muscle Type IIIb (~15% of patients) Enzyme deficient in liver Type IIIc Loss of glucosidase activity Type IIId Loss of transferase activity

GSD Type III AGL gene 35 exons, 85 kb on Chr 1p21 Type IIIa Majority (65%) of mutations are nonsense, frameshift or splice site mutations Common changes p.arg408x, c.4260-12a>g, p.arg864x Rare changes 118 mutations reported Type IIIb Exon 3 nonsense mutations c.16c>t, p.gln6x, c.18_19delga, p.gln6hisfsx20 c.22c>t, p.arg8x

GSD Type III AGL mutations From: JL Goldstein et al 2010. Genet Med 12:424 430

GSD Type III Genetic analysis Allows distinction between type IIIa and IIIb Some indication of severity eg c.4260-12a>g is mild mutation Correlates with leukocyte enzyme assay

Cases 2 and 3 Patient, aged 5 years Permanent hepatomegaly Fasting <3 hours Permanent CK elevation Cardiomyopathy Fatigue not observed Leuk Debrancher: 5.7 Normal range: 26.8-105 nmol glu/mg protein/hour RBC Glycogen: 565 Normal range: 5.7-135 µg/g Hb p.arg408x homozygote Patient, aged 20 years Hepatomegaly till 16 years Normal feeding Normal CK No Cardiomyopathy Periodic fatigue Leuk Debrancher: 0.69 Normal range: 26.8-105 nmol glu/mg protein/hour RBC Glycogen: 726 Normal range: 5.7-135 µg/g Hb p.arg8x and c.4260-12a>g

Glycogen Synthesis and Breakdown Glycogen Synthase Branching Enzyme Type IV GBE gene Glycogen Sheffield Phosphorylase Kinase Phosphorylase UDPGlucose Alpha-1,6 Limit dextrin Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose

GSD Type IV Also known as Anderson Disease Deficiency of glycogen branching enzyme Autosomal recessive GBE1 gene 16 exons, 262 kb on Chr 3p14 Rare

GSD Type IV 20 Patients reported 34 unique mutations Some phenotype/genotype correlation Wide range of phenotypes Congenital presentation to polyglucosan body disease Genetic analysis allows prenatal diagnosis Identification of carriers

Glycogen Synthesis and Breakdown Type 0 GYS2 gene Glycogen Synthase Branching Enzyme Glycogen Sheffield Phosphorylase Kinase Phosphorylase UDPGlucose Alpha-1,6 Limit dextrin Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose

GSD Type 0 Deficiency of glycogen synthase Autosomal recessive GYS2 gene Rare 16 exons, 69kb on Chr 12p12.2

GSD Type 0 Clinical symptoms Ketotic hypoglycaemia Post-prandial hyperglycaemia and hyperlactataemia Low activity in liver biopsy Molecular analysis avoids liver biopsy

GYS2 Mutations From Weinstein et al 2006. Mol Genet Metab 87: 284-288.

Glycogen Synthesis and Breakdown Glycogen Synthase Branching Enzyme Glycogen Sheffield Phosphorylase Kinase Phosphorylase UDPGlucose Alpha-1,6 Limit dextrin Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose

Glycogen Synthesis and Breakdown Alpha-1,6 Sheffield Uridine Diphosphoglucose Pyrophosphorylase Glucose Glucokinase Phosphoglucose Isomerase Alpha-1,4 Glucose 1-P Glucose 6-P Debranching Enzyme G-6-Phosphatase Glucose

Glycogen Synthesis and Breakdown Alpha-1,6 Sheffield Uridine Diphosphoglucose Pyrophosphorylase Glucose Type VII Glucokinase Phosphoglucose Isomerase Phosphofructokinase Alpha-1,4 Glucose 1-P Glucose 6-P Fructose 6-P Fructose-1,6-bisphosphate Pyruvate Debranching Enzyme G-6-Phosphatase Glucose Glucose Phosphate Isomerase FBP1 deficiency Fructose-1,6-bisphosphatase

GSD Type VII Also known as Tarui disease First identified in 1965 Deficiency of muscle phosphofructokinase Homo-tetramer Three isoforms muscle, liver and platelet types Autosomal recessive inheritance PFKM gene Located on 12q13 24 exons covering 30kb Rare

GSD Type VII Type VIIa Classical Exercise intolerance Muscle cramps and pain after exercise Type VIIb Late onset Mean age of onset 55 years Progressive fatigue and weakness Type VIIc Infantile Floppy and hypotonic babies Die within 1 year Type VIId Haemolytic No muscle symptoms Severe haemolysis

PFKM gene and Mutations 15 mutations reported Genetic analysis? avoid muscle biopsy Prenatal diagnosis Differential splicing From: Nakajima From et al Nakajima 2002. Current et al 2002. Molecular Current Molecular Medicine 2: 2:197-212 197-212.

Glycogen Synthesis and Breakdown Alpha-1,6 Sheffield Uridine Diphosphoglucose Pyrophosphorylase Glucose Type VII Glucokinase Phosphoglucose Isomerase Phosphofructokinase Alpha-1,4 Glucose 1-P Glucose 6-P Fructose 6-P Fructose-1,6-bisphosphate Pyruvate Debranching Enzyme G-6-Phosphatase Glucose Glucose Phosphate Isomerase FBP1 deficiency Fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase Clinical Symptoms Hypoglycaemia Lactic acidosis Glyceroluria Hepatomegaly Autosomal Recessive FBP1 gene 7 exons, 31 kb on Chr 9q22.3

FBP1 Gene Mutations -18 point mutations -Exon 1 deletion p.n12fs p.e30x p.g164s p.q229x p.n213k p.d236fs p.k270fs p.a177d p.g261a p.p284r p.f194s p.g294v p.s321fs p.d323fs p.v325a p.d122a p.g207fs p.e281k

Fructose-1,6-bisphosphatase Molecular analysis Avoids liver biopsy Diagnosis when enzymology not available No clear genotype/phenotype correlation

Case 4 Presented at 2 years with hypoglycaemic coma following intercurrent illness Mild hepatomegaly Slight hypertransaminasemia (135 U/l) with lactic acidosis Lactic aciduria with ketonuria and slight excretion of glycerol Normal FBPase activity in leukocytes Decreased activity of FBPase in liver (2.1, NV: 22 and 26 mol/min/mg ptn) Decreased glycogen content in liver (15.1 mg/g of tissue; NR: 20-50). Genetic analysis of FBP1 gene: c.618dela, p.g207fs homozygote

GSD Type II Also known as Pompe Disease, acid α-glucosidase deficiency or acid maltase deficiency Autosomal recessive Lysomal storage disease - accumulation of glycogen in all tissues 1 in 40,000 live births Treatment - Enzyme replacement therapy Myozyme (Genzyme)

GSD Type II Infantile onset (1 month) Cardiomegaly, cardiomyopathy, hepatomegaly, weakness and hypotonia Death due to cardiorespiratory failure in first year Late or adult onset (20-60 years) Slowly progressive myopathy affecting skeletal muscle Involvement of diaphragm and accessory muscle of respiration leads to respiratory failure Cardiomyopathy generally absent Symptoms correlate with residual enzyme activity

GAA gene Mutations Common Mutations c.-45t>g - Mild phenotype c.525del - severe phenotype Rare mutations >150 listed on mutation database at: http://www.pompecenter.nl/

Type 0 Ia Ib III IV VI IXauto IXx Totals Total Samples 53 39 25 75 15 39 32 90 368 Confirmed Diagnosis Diagnosis Unconfirmed Investigated Further Diagnosis Changed 3 (6%) 50 (95%) 25 (64%) 11 (28%) 14 (56%) 7 (28%) 53 (71%) 19 (25%) 5 (33%) 9 (60%) 11 (28%) 10 (26%) 13 (41%) 17 (53%) 55 (61%) 23 (26%) 179 (49%) 146 (39%) 3 9 5 9 1 22 9 27 85 0 (0%) 3 (8%) 4 (16%) 3 (4%) 1 (7%) 18 (46%) 2 (6%) 12 (13%) 0 1 1 Ia 2 2 Ib 3 3 III 1 1 VI 1 2 2 5 IX X-linked 2 2 15 19 IX Autosomal 1 PHKG2 2 PHKB 6 PHKG2 3 PHKB 43 (12%) 7 PHKG2 5 PHKB

Conclusions analysis can: Provide a definitive diagnosis Replace liver or muscle biopsy Allow carrier testing and prenatal diagnosis Change diagnosis and inheritance patterns In some cases indicate prognosis